Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - MABVAX THERAPEUTICS HOLDINGS, INC. | mbvx8k_jan302018.htm |
Exhibit 99.1
MabVax Receives Notice of SEC Investigation and Examination of
Certain Registration Statements
San Diego, January 30, 2018 -- MabVax Therapeutics
Holdings, Inc. (NASDAQ: MBVX) (“MabVax” or the
“Company”), a clinical-stage biotechnology company
focused on the development of antibody-based products to address
unmet medical needs in the treatment of cancer, today announced
that it received notice that the Securities and Exchange Commission
(“SEC”) was conducting an investigation and examination
pursuant to Section 8(e) of the Securities Act of 1933, as amended,
relating to certain of the Company’s registration statements
(and amendments thereto). The Company intends to cooperate fully
with the SEC’s examination.
About MabVax
MabVax
Therapeutics Holdings, Inc. is a clinical-stage biotechnology
company with a fully human antibody discovery platform focused on
the rapid translation into clinical development of products to
address unmet medical needs in the treatment of cancer. Our
antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb)
that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is
currently in Phase 1 clinical trials as a therapeutic agent for
patients with pancreatic cancer and other CA19-9 positive tumors.
CA19-9 is expressed in over 90% of pancreatic cancers and in other
diseases including small cell lung and GI cancers. CA19-9 plays an
important role in tumor adhesion and metastasis, and is a marker of
an aggressive cancer phenotype. CA19-9 serum levels are considered
a valuable adjunct in the diagnosis, prognosis and treatment
monitoring of pancreatic cancer. With our collaborators including
Memorial Sloan Kettering Cancer Center, Sarah Cannon Research
Institute, Honor Health and Imaging Endpoints, we have treated 50
patients with either our therapeutic antibody designated as
MVT-5873 or our PET imaging diagnostic product designated as
MVT-2163 in Phase 1 clinical studies, and demonstrated early safety
and specificity for the target. Patient dosing has commenced for
our lead development program in Phase 1 clinical study of the
Company's radioimmunotherapy product MVT-1075. For additional
information, please visit the Company's website, www.mabvax.com.
Forward-Looking Statements
This
press release may contain forward looking statements. These
forward-looking statements are based upon current expectations of
the Company and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including risks and uncertainties related to the
Order. Please review the Company's periodic filings with the
Securities and Exchange Commission, including the factors described
in the section entitled "Risk Factors" in its annual report on Form
10-K for the fiscal year ended December 31, 2016, as amended and
supplemented from time to time and the Company's Quarterly
Reports on Form 10-Q and other filings submitted by the Company to
the SEC, copies of which may be obtained from the SEC's website
at www.sec.gov. The parties do not
undertake any obligation to update forward-looking statements
contained in this press release.
|
|
Investor Contact:
Jenene
Thomas
Jenene
Thomas Communications, LLC
Phone:
+1 (908) 938-1475
Email: jtc@jenenethomascommunications.com